IntraBiotics and Cetek to Collaborate on Screening to Identify Antibacterial And Antifungal Drug Leads

Apr 17, 2001, 01:00 ET from IntraBiotics Pharmaceuticals, Inc.

    MOUNTAIN VIEW, Calif. and MARLBOROUGH, Mass., April 17 /PRNewswire/ --
 IntraBiotics Pharmaceuticals, Inc. (Nasdaq:   IBPI) and privately held
 Cetek Corporation today announced a research collaboration that will allow
 IntraBiotics to utilize Cetek's proprietary capillary electrophoresis (CE)
 screening technology to identify compounds with antibacterial or antifungal
 properties.
     Kenneth J. Kelley, Chairman and Chief Executive Officer of IntraBiotics,
 said, "We are extremely pleased to collaborate with Cetek Corporation.  We
 perceive a rich opportunity in natural product screening, thanks to recent
 advances in screening technology such as those developed by Cetek.  The broad
 IntraBiotics product pipeline currently has programs at all stages of
 development -- from research to phase III clinical trials.  By leveraging the
 most advanced tools available, we look to this collaboration to help sustain a
 stream of leads into that product development pipeline for the future."
     James L. Waters, President of Cetek, said, "We are excited to be working
 with IntraBiotics in applying Cetek's technology to their novel targets.  Our
 screening technology is gaining wide acceptance as the technology of choice
 for screening complex natural product extracts.  We are pleased to be applying
 it to IntraBiotics' antimicrobial agents."
     John Fiddes, Ph.D., Chief Technology Officer for IntraBiotics, explained
 that the great majority of antimicrobial agents on the market today are either
 physically or intellectually derived from natural products.  "We see
 particular value in Cetek's CE screening technology because it should allow
 very effective mining of all active molecules in complex natural product
 extracts," Dr. Fiddes said.  "It will allow rapid exploitation of novel
 targets and streamline the screening of natural products, a combination that
 IntraBiotics views as very promising for the discovery of novel antimicrobial
 agents."
     IntraBiotics recently announced research collaborations with Diversa
 Corporation to discover and develop antimicrobials identified from Diversa's
 recombinant environmental libraries, and with Albany Molecular Research, Inc.
 to access that company's natural product libraries.  "These recent
 collaborations, combined with access to Cetek's advanced screening technology,
 provide a discovery effort to complement the established development focus of
 our company," Mr. Kelley added.
     IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a
 biopharmaceutical company engaged in the development of novel antibacterial
 and antifungal drugs for the treatment and prevention of serious infectious
 diseases, including those caused by multi-drug resistant pathogens.  The
 company's technology consists of several distinct chemical classes of
 antibacterials and antifungals.  IntraBiotics' lead product candidate,
 iseganan HCl oral solution (formerly referred to as Protegrin IB-367 Rinse)
 for oral mucositis is now in phase III clinical studies.  IntraBiotics also is
 conducting a phase III clinical trial of a second product, ramoplanin oral
 powder, for prevention of vancomycin-resistant enterococci (VRE) bloodstream
 infections in cancer patients.  IntraBiotics has several additional drug
 candidates in earlier stage research and development.  Additional information
 is available at the company's web site:  www.intrabiotics.com.
     Cetek Corporation, a privately held drug discovery company, applies its
 proprietary capillary electrophoresis (CE) screening technology to develop
 high-throughput screening assays for drug targets.  The Cetek CE Assay can
 quickly discover valuable "hits" in synthetic libraries, combinatorial
 mixtures, and natural product extracts.  This proprietary technology combines
 laser-induced fluorescence or UV detection with high resolution CE.  The
 technology was originally developed in Prof. Barry Karger's laboratory at the
 Barnett Institute of Northeastern University and is licensed exclusively to
 Cetek.  In addition to the CE Assay, Cetek is adding libraries,
 fractionation/isolation and analytical capabilities to provide identified hits
 to its clients.  Cetek has collaborations with pharmaceutical and
 biotechnology companies in North America, Europe and Japan.  Additional
 information is available at Cetek's web site:  www.cetek.com.
     Statements in this press release that are not strictly historical are
 "forward-looking" and involve a high degree of risk and uncertainty.  These
 include statements related to the potential discovery and/or development of
 novel pharmaceutical compounds, leads, or products, and the identification of
 drugs and their derivatives.  These forward-looking statements are subject to
 the occurrence of many events outside of IntraBiotics' or Cetek's control and
 are subject to various risk factors that could cause results to differ
 materially from those expressed in any forward-looking statement.  Factors
 that could cause or contribute to differences include, but are not limited to,
 the inherent risks of product development failure, the uncertainty of clinical
 outcomes, and risks related to proprietary rights.  These risk factors and
 others are more fully described in documents on file with the Securities and
 Exchange Commission, including, but not limited to, IntraBiotics' Report on
 Form 10-K for the period ending December 31, 2000 as well as the Company's
 other SEC filings.
 
 

SOURCE IntraBiotics Pharmaceuticals, Inc.
    MOUNTAIN VIEW, Calif. and MARLBOROUGH, Mass., April 17 /PRNewswire/ --
 IntraBiotics Pharmaceuticals, Inc. (Nasdaq:   IBPI) and privately held
 Cetek Corporation today announced a research collaboration that will allow
 IntraBiotics to utilize Cetek's proprietary capillary electrophoresis (CE)
 screening technology to identify compounds with antibacterial or antifungal
 properties.
     Kenneth J. Kelley, Chairman and Chief Executive Officer of IntraBiotics,
 said, "We are extremely pleased to collaborate with Cetek Corporation.  We
 perceive a rich opportunity in natural product screening, thanks to recent
 advances in screening technology such as those developed by Cetek.  The broad
 IntraBiotics product pipeline currently has programs at all stages of
 development -- from research to phase III clinical trials.  By leveraging the
 most advanced tools available, we look to this collaboration to help sustain a
 stream of leads into that product development pipeline for the future."
     James L. Waters, President of Cetek, said, "We are excited to be working
 with IntraBiotics in applying Cetek's technology to their novel targets.  Our
 screening technology is gaining wide acceptance as the technology of choice
 for screening complex natural product extracts.  We are pleased to be applying
 it to IntraBiotics' antimicrobial agents."
     John Fiddes, Ph.D., Chief Technology Officer for IntraBiotics, explained
 that the great majority of antimicrobial agents on the market today are either
 physically or intellectually derived from natural products.  "We see
 particular value in Cetek's CE screening technology because it should allow
 very effective mining of all active molecules in complex natural product
 extracts," Dr. Fiddes said.  "It will allow rapid exploitation of novel
 targets and streamline the screening of natural products, a combination that
 IntraBiotics views as very promising for the discovery of novel antimicrobial
 agents."
     IntraBiotics recently announced research collaborations with Diversa
 Corporation to discover and develop antimicrobials identified from Diversa's
 recombinant environmental libraries, and with Albany Molecular Research, Inc.
 to access that company's natural product libraries.  "These recent
 collaborations, combined with access to Cetek's advanced screening technology,
 provide a discovery effort to complement the established development focus of
 our company," Mr. Kelley added.
     IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a
 biopharmaceutical company engaged in the development of novel antibacterial
 and antifungal drugs for the treatment and prevention of serious infectious
 diseases, including those caused by multi-drug resistant pathogens.  The
 company's technology consists of several distinct chemical classes of
 antibacterials and antifungals.  IntraBiotics' lead product candidate,
 iseganan HCl oral solution (formerly referred to as Protegrin IB-367 Rinse)
 for oral mucositis is now in phase III clinical studies.  IntraBiotics also is
 conducting a phase III clinical trial of a second product, ramoplanin oral
 powder, for prevention of vancomycin-resistant enterococci (VRE) bloodstream
 infections in cancer patients.  IntraBiotics has several additional drug
 candidates in earlier stage research and development.  Additional information
 is available at the company's web site:  www.intrabiotics.com.
     Cetek Corporation, a privately held drug discovery company, applies its
 proprietary capillary electrophoresis (CE) screening technology to develop
 high-throughput screening assays for drug targets.  The Cetek CE Assay can
 quickly discover valuable "hits" in synthetic libraries, combinatorial
 mixtures, and natural product extracts.  This proprietary technology combines
 laser-induced fluorescence or UV detection with high resolution CE.  The
 technology was originally developed in Prof. Barry Karger's laboratory at the
 Barnett Institute of Northeastern University and is licensed exclusively to
 Cetek.  In addition to the CE Assay, Cetek is adding libraries,
 fractionation/isolation and analytical capabilities to provide identified hits
 to its clients.  Cetek has collaborations with pharmaceutical and
 biotechnology companies in North America, Europe and Japan.  Additional
 information is available at Cetek's web site:  www.cetek.com.
     Statements in this press release that are not strictly historical are
 "forward-looking" and involve a high degree of risk and uncertainty.  These
 include statements related to the potential discovery and/or development of
 novel pharmaceutical compounds, leads, or products, and the identification of
 drugs and their derivatives.  These forward-looking statements are subject to
 the occurrence of many events outside of IntraBiotics' or Cetek's control and
 are subject to various risk factors that could cause results to differ
 materially from those expressed in any forward-looking statement.  Factors
 that could cause or contribute to differences include, but are not limited to,
 the inherent risks of product development failure, the uncertainty of clinical
 outcomes, and risks related to proprietary rights.  These risk factors and
 others are more fully described in documents on file with the Securities and
 Exchange Commission, including, but not limited to, IntraBiotics' Report on
 Form 10-K for the period ending December 31, 2000 as well as the Company's
 other SEC filings.
 
 SOURCE  IntraBiotics Pharmaceuticals, Inc.